Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: Relationship with p53 and MDM2 protein expression

American Journal of Pathology

Volumn 153, Issue 6, 1998, Pages 1749-1765

  Gorgoulis, Vassilis G ^a,d   Zacharatos, Panayotis ^a   Kotsinas, Athanassios ^a   Liloglou, Triantofillos ^b   Kyroudi, Aspasia ^a   Veslemes, Marinos ^a   Rassidakis, Antonios ^a   Halazonetis, Thanos D ^c   Field, John K ^b   Kittas, Christos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Roy Castle   (United Kingdom)

^c WISTAR INSTITUTE   (United States)

^d NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; MICROSATELLITE DNA; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHROMOSOMAL LOCALIZATION; CHROMOSOME 9P; CLINICAL ARTICLE; FEMALE; GENE INACTIVATION; GENE LOCUS; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LUNG NON SMALL CELL CANCER; MALE; MICROSATELLITE INSTABILITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; SMOKING; TUMOR SUPPRESSOR GENE;

EID: 0031740916     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65690-8     Document Type: Article

References (90)

1. Linnoila RI, Aisner SC: Pathology of lung cancer: an exercise in classification. Lung Cancer. Edited by Johnson BE, Johnson DH. New York, Wiley-Liss, 1995, pp 73-95
2. Cordon-Cardo C: Mutations of cell cycle regulators. Am J Pathol 1995, 147:545-560
3. ARF. Cell 1997, 91:551-558
4. Serrano M, Hannon G, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707
5. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440
6. Knudson AG: Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993, 90:10914-10921
7. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756
8. Cairns P, Mao L, Merlo A: Rates of the p16 (MTS1) mutations in primary tumours with 9p loss. Science 1994, 265:415-416
9. Okamoto A, Demetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennet WP, Forrester K, Gerwin B, Serrano M, Beach DH, Herris CC: Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. USA 1994, 91:11045-11049
10. Spruck CH III, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA: p16 gene in uncultured tumours. Nature 1994, 370:183-184
11. Zhang S-Y, Klien-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL: Higher frequency of the alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumours of the head and neck. Cancer Res 1994, 54:5050-50503
12. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes C, Piantadosi S, Cardon-Cardo C, Slamon DJ, The Lung Cancer Study Group: Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. Oncogene 1993, 8:1913-1919
13. INK4 expression in primary lung cancers and cell lines. Cancer Res 1995, 55: 505-509
14. INKB in primary and metastatic lung cancer. Cancer Res 1995, 55:1448-1451
15. Shimizu T, Sekiya T: Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers. Int J Cancer 1995, 63:616-620
16. Xiao S, Joseph DL, Vijg J, Fletcher JA: Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res 1995, 55:2968-2971
17. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T: In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 1995, 55:514-517
18. ink4a and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene 1995, 11:1843-1851
19. INKB and p18 genes in primary non-small-cell lung cancers. Int J Cancer 1996, 65:734-739
20. Sakaguchi M, Fujii Y, Hirabayashi H, Yoon H-E, Komoto Y, Oue T, Kusafuka T, Okada A, Matsuda H: Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int J Cancer 1996, 65:442-445
21. INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res 1996, 56: 5557-5562
22. INK4a expression in resected non-small cell lung tumors. Cancer Res 1996, 56:3415-3420
23. Marchetti A, Buttitta F, Pellegrini S, Bertacca G, Chella A, Carnicelli V, Tognoni V, Filardo A, Angeletti CA, Bevilacqua G: Alterations of p16(MTS1) in node-positive non-small cell lung carcinomas. J Pathol 1997, 181:178-182
24. INK4 expression in non-small cell lung carcinoma. Cancer 1997, 80:389-395
25. Betticher DC, White GRM, Vonlanthen S, Liu X, Kappeler A, Altermatt HJ, Thatcher N, Heighway J: G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer 1997, 74:556-562
26. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sydranski D: 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1995, 1:686-692
27. Geradts J, Hu S-X, Lincoln CE, Benedict WF, Xu H-J: Aberrant Rb gene expression in routinely processed, archival tumor tissues determined by three different anti-Rb antibodies. Int J Cancer 1994, 58:161-167
28. Higashiyama M, Doi O, Kodama K, Yochouchi H, Tateishi R: Retinoblastoma protein expression in lung cancer: an immunohistochemical analysis. Oncology 1994, 51:544-551
29. Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzke RA, Kim YW, Fedorko J, Oie H, Johnson BE, Mulshine JL, Minna JD, Gazdar AF, Kaye FJ: Rb protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small carcinoma, and mesothelioma. Oncogene 1994, 9:2441-2448
30. Xu H-L, Hu S-X, Cagle PT, Moore GE, Benedict WF: Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res 1991, 51:2735-2739
31. Shiio Y, Yamamoto T, Yamaguchi N: Negative regulation of Rb expression by the p53 gene product. Proc Natl Acad Sci USA 1992, 89:5206-5210
32. Xiao ZX, Chen J, Levine AJ, Modjtahedi N, Xing J, Sellers WR, Livingston DM: Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 1995, 375:694-698
33. Piette J, Neel H, Marechal V. Mdm2: keeping p53 under control. Oncogene 1997, 15:1001-1010
34. Haines DS. The mdm2 proto-oncogene. Leuk Lymphoma 1996, 26: 227-238
35. Gorgoulis V, Rassidakis G, Karameris A, Papastamatiou H, Trigidou R, Veslemes M, Rassidakis A, Kittas C: Immunohistochemical and molecular evaluation of the MDM2 gene product in bronchogenic carcinoma. Mod Pathol 1996, 9:544-554
36. Gorgoulis V, Zoumpourlis V, Rassidakis G, Karameris A, Rassidakis A, Spandidos DA, Kittas C: A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. J Pathol 1996, 180:129-137
37. Gorgoulis VG, Zacharatos PV, Manolis E, Ikonomopoulos JA, Damalas A, Lamprinopoulos C, Rassidakis GZ, Zoumpourlis V, Kotsinas A, Rassidakis AN, Halazonetis TD, Kittas C: Effects of p53 mutants derived from lung carcinomas on the p53 responsive element (p53RE) of the MDM2 gene. Br J Cancer 1998, 77:378-384
38. Wiest JS, Franklin WA, Otstot JT, Forbey K, Varella-Garcia M, Rao K, Drabkin H, Gemmill R, Ahrent S, Sidransky D, Saccomanno G, Fountain JW, Anderson MW: Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. Cancer Res 1997, 57:1-7
39. World Health Organization: The World Health Organization histologic typing of lung tumours. Am J Clin Pathol 1982, 77:123-136
40. Geradts J, Wilson PA: High frequency of aberrant p16ink4A expression in human breast cancer. Am J Pathol 1996, 149:15-20
41. Whetsell L, Maw G, Nadon N, Ringer D, Schaefer F: Polymerase chain reaction microanalysis of tumors from stained histological slides. Oncogene 1995, 7:581-585
42. Davis LG, Dibner MD, Battey JF: Basic Methods in Molecular Biology. Amsterdam, Elsevier Science Publishing, 1986
43. Fong KM, Zimmermann PV, Smith PJ: Microsatellite instability and other molecular abnormalities in non-small cell lung cancer. Cancer Res 1995, 55:28-30
44. INK4 (MTS1) gene inactivation in testicular germ cell tumors. Am J Pathol 1997, 151:859-865
45. Gorgoulis V, Zoumpourlis V, Rassidakis G, Karameris A, Barbatis C, Spandidos DA, Kittas C: Molecular analysis of p53 gene in laryngeal pre-malignant and malignant lesions: p53 protein immunohistochemical expression is positively related to proliferating cell nuclear antigen labelling index. Virchows Arch 1995, 426:339-344
46. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1995, 54:4855-4878
47. Merlo A, Mabry M, Gabrielson E, Vollmer R, Baylin SB, Sidransky D: Frequent microsatellite instability in primary small cell lung cancer. Cancer Res 1993, 54:2098-2101
48. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998, 92:713-723
49. Zhang Y, Xiong Y, Yarbrourgh WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998, 92:725-734
50. Otterson GA, Kleif SN, Chen W, Coxon AB, Kaye FJ: CDKN2 gene silencing in lung cancer by DNA hypermethylation, and kinetics of p16INK4 protein induction by 5-aza 2′ deoxycytidine. Oncogene 1995, 11:1211-1216
51. ARF. Cell 1997, 91:555-558
52. Olopade OI, Pomykala HM, Hagos F, Sveen LW, Espinosa R III, Dreyling MH, Gursky S, Stadler WM, Le Beau MM, Bolander SK: Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci USA 1995, 92:6489-6493
53. Geradts J, Kratzke RA, Niehans GA, Lincoln CE: Immunohistochemical detection of the cyclin dependent kinase inhibitor 2/multiple suppressor gene 1 (CDKN2/MTS1) product p16ink4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995, 55:6006-6011
54. INK4. Cancer Res 1994, 54:5816-5820
55. Xu H-J, Hu S-X, Benedict WF: Lack of nuclear RB protein staining in GO/middle G1 cells: correlation to changes in total RB protein level. Oncogene 1991, 6:1139-1146
56. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J: Retinoblastoma protein dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995, 375:503-506
57. Okamoto A, Detnetrick DJ, Spillare EA, Hagiwara K, Hussain SP, Bennet WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC: Mutations and altered expression ot p16INK4 in human cancer. Proc Natl Acad Sci Usa 1994, 91:11045-11049
58. Zambetti GP, Levine AJ: A comparison of the biological activities of wild type and mutant p53. FASEB J 1993, 7:855-865
59. INK4A inactivation in non-small cell lung lines. Cancer Res 1995, 55:6200-6209
60. Merlo A, Gabrielson E, Mabry M, Vollmer R, Baylin SB, Sydranski D: Homozygous deletion on chromosome 9p and loss of heterozygosity on 9p, 6p, and 6q in primary human small cell lung cancer. Cancer Res 1994, 54:2322-2326
61. Packenham JP, Taylor JA, White CM, Anna CH, Barrett JC, Devereux TR: Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers. Clin Cancer Res 1995, 1:687-690
62. Shimizu T, Sekiya T: Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers. Int J Cancer 1995, 63:616-620
63. Mead LJ, Gillespie MT, Hung JY, Rane US, Rayeroux KC, Irving LB, Campbell LJ: Frequent loss of heterozygosity in early non-small cell lung cancers at chromosome 9p21 proximal to the CDKN2a gene. Int J Cancer 1997, 71:213-217
64. Vos S, Miller C, Takeuchi S, Combart A, Cho S, Koeffler H: Alteration of CDKN2 (p16) in non-small cell lung cancer. Genes Chromosomes & Cancer 1995, 14:164-170
65. Neville EM, Stewart M, Myskow M, Donnelly RJ, Field JK: Loss of heterozygosity at 9p23 defines a novel locus in non-small cell cancer. Oncogene 1995, 11:581-585
66. Gilmore AP, Ohanian V, Spurr NK, Critchley DR: Localisation of the human gene encoding the cytoskeletal protein talin to chromosome 9p. Hum Genet 1995, 96:221-224
67. Albiges-Rizo C, Frachet P, Block MR: Down regulation of talin alters cell adhesion and the processing of the α5β1 integrin. J Cell Sci 1995, 108:3317-3329
68. Jiricny J: Colon cancer and DNA repair: have mismatches met their match? Trends Genet 1994, 10:164-168
69. Peltomaki P, Lothe RA, Aaltonen LA, Pylkkanen L, Nystrom-Lathi M, Secura R, David L, Holm R, Ryberg D, Haugen A, Brogger A, Borresen A-L, de la Chapelle A: Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res 1993, 53:5853-5855
70. Shridhar V, Siegfried J, Hunt J, del Mar Alonso M, Smith DI: Genetic instability of microsatellite sequences in many non-small cell lung carcinomas. Cancer Res 1994, 54:2084-2087
71. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 1996, 87:159-170
72. Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C: Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 1995, 55:493-497
73. INK4 protein is restricted to the subset of lung cancer lines that retains wild type RB. Oncogene 1994, 9:3375-3378
74. INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 1996, 87: 4949-4958
75. ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 1995, 92:6289-6293
76. Bernards R: E2F: a nodal point in cell cycle regulation. Biochem Biophys Acta 1997, 1333:M33-M40
77. Kishimoto Y, Sugio K, Hung JY, Virmani AK, McIntire DD, Minna JD, Gazdar AF: Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst 1995, 87:1224-1229
78. El-Naggar AK, Lai S, Clayman G, Lee J-KJ, Luna MA, Goepfert H, Batsakis JG: Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am J Pathol 1997, 151:1767-1774
79. Lianes P, Orlow I, Zhang Z-F, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C: Altered patterns of MDM-2 expression in human bladder cancer. J Natl Cancer Inst 1994, 86:1325-1330
80. Zacharatos P, Gorgoulis V, Kotsinas A, Kanavaros P, Zoumpourlis V, Veslemes M, Halazonetis T, Kittas C: Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE): a comparative study between the p53REs of the MDM2, WAF1/Cip1 and Bax genes in lung cancer environment. Abstract presented at the 9th p53 Workshop, Crete, May 9 to 14, 1998
81. Marchetti A, Buttitta F, Pellegrini S, Merlo G, Chella A, Angeletti CA, Bevilacqua G: mdm2 gene amplification and overexpression in non-small cell lung carcinoma with accumulation of the p53 protein in the absence of p53 gene mutation. Diagn Mol Pathol 1995, 4:93-97
82. Momand J, Zambetti GP: Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene 1996, 12:2279-2289
83. Shieh S-Y, Ikeda M, Taya Y, Prives C: DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91:325-334
84. Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299
85. White E: p53, guardian of Rb. Nature 1994, 371:21-22
86. Murakami Y, Hirayashi K, Hirohashi S, Sekiya T: Aberrations of the tumor suppressor p53 and the retinoblastoma genes in human hepatocellular carcinomas. Cancer Res 1991, 51:5520-5525
87. Cheng J, Mass M: Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 1990, 10:5502-5509
88. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T: Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genet 1994, 7:480-484
89. Kalemkerian GP: Biology of lung cancer. Curr Opin Oncol 1994, 6:147-155
90. Groeger AM, Esposito V, Mueller MR, Caputi M, Kaiser HE, Giordano A: Advances in the understanding of lung cancer. Anticancer Res 1997, 17:2519-2522